Pancreatic Cancer Treatment: An Evidence Synthesis on Resectability, Neoadjuvant Therapy, Adjuvant Regimens, and First-Line Metastatic Care
An evidence synthesis spanning the PREOPANC and ESPAC-5F neoadjuvant trials, the PRODIGE 24 adjuvant regimen, the NAPOLI 3 NALIRIFOX trial in metastatic disease, and consensus resectability criteria.
One-Minute Takeaway on Pancreatic Cancer Treatment
One-Minute Takeaway
- Pancreatic cancer treatment is fundamentally stratified by resectability — resectable, borderline resectable, locally advanced, and metastatic — with each category mapping to a distinct evidence-based pathway.
- PREOPANC long-term follow-up demonstrated 5-year overall survival of 20.5% with neoadjuvant chemoradiation versus 6.5% with upfront surgery in resectable and borderline resectable disease (HR 0.73 for OS).
- ESPAC-5F supports neoadjuvant chemotherapy over immediate surgery in borderline resectable disease, with 1-year survival favouring the neoadjuvant arms across regimens.
- For resected disease, modified FOLFIRINOX is the adjuvant standard in fit patients (PRODIGE 24 median OS 54.4 vs 35.0 months versus gemcitabine).
- For metastatic disease, NAPOLI 3 established NALIRIFOX as a first-line option with median OS 11.1 versus 9.2 months compared with gemcitabine plus nab-paclitaxel.
Why Pancreatic Cancer Treatment Decisions Matter
Pancreatic ductal adenocarcinoma is on track to become the second-leading cause of cancer death in many high-income countries within this decade. Five-year overall survival across all stages remains approximately 12%, but for the minority of patients with resectable disease who undergo modern multimodality therapy, outcomes have meaningfully improved over the past 15 years.
Modern pancreatic cancer treatment rests on three converging pillars of randomised evidence: neoadjuvant therapy in resectable and borderline resectable disease is now supported by phase 3 trials; adjuvant FOLFIRINOX has become the post-resection standard for fit patients; and NALIRIFOX has joined FOLFIRINOX and gemcitabine plus nab-paclitaxel as a validated first-line metastatic regimen in modern pancreatic cancer treatment.
Aligning surgical and oncologic decisions with the strongest available evidence is one of the highest-leverage interventions in modern pancreatic cancer treatment. Multidisciplinary tumor board review, accurate radiographic staging, and timely access to systemic therapy together determine whether a patient receives the regimen with the largest survival benefit demonstrated in their specific disease setting.
What Evidence Was Reviewed
This synthesis draws on landmark phase 3 trials in neoadjuvant therapy (PREOPANC, ESPAC-5F), adjuvant therapy (PRODIGE 24, ESPAC-4), first-line metastatic disease (NAPOLI 3, PRODIGE 4, MPACT), the A021501 phase 2 borderline-resectable trial, and consensus statements on resectability classification.
Studies were selected for design strength, duration of follow-up, and direct relevance to pancreatic cancer treatment decisions encountered in routine multidisciplinary practice. Priority was given to multicentre randomised trials with mature survival data, and to consensus statements that synthesise study-level evidence into actionable definitions.
| Study / Source | Design | Population (n) | Comparison / Question | Key Outcome |
|---|---|---|---|---|
| PREOPANC long-term (Versteijne 2022) | Phase 3 RCT, extended follow-up | 246 | Neoadjuvant CRT vs upfront surgery | 5-yr OS 20.5% vs 6.5%; HR 0.73 |
| PREOPANC primary (Versteijne 2020) | Phase 3 RCT | 246 | Neoadjuvant CRT vs upfront surgery | R0 resection 71% vs 40% |
| ESPAC-5F (Ghaneh 2023) | Phase 2 RCT, 4-arm | 90 | Immediate surgery vs neoadjuvant chemo/CRT | 1-yr OS favoured neoadjuvant arms |
| A021501 (Katz 2022) | Phase 2 RCT | 126 | mFOLFIRINOX ± SBRT in borderline resectable | Both arms feasible; chemo-only arm met primary endpoint |
| PRODIGE 24 (Conroy 2018) | Phase 3 RCT | 493 | Adjuvant mFOLFIRINOX vs gemcitabine | Median OS 54.4 vs 35.0 mo; HR 0.64 |
| ESPAC-4 (Neoptolemos 2017) | Phase 3 RCT | 730 | Adjuvant gemcitabine + capecitabine vs gemcitabine | Median OS 28.0 vs 25.5 mo; HR 0.82 |
| PRODIGE 4 / ACCORD 11 (Conroy 2011) | Phase 3 RCT | 342 | FOLFIRINOX vs gemcitabine in metastatic | Median OS 11.1 vs 6.8 mo |
| MPACT (Von Hoff 2013) | Phase 3 RCT | 861 | Gemcitabine + nab-paclitaxel vs gemcitabine | Median OS 8.5 vs 6.7 mo; HR 0.72 |
| NAPOLI 3 (Wainberg 2023) | Phase 3 RCT | 770 | NALIRIFOX vs gemcitabine + nab-paclitaxel | Median OS 11.1 vs 9.2 mo; HR 0.84 |
| NAPOLI-1 (Wang-Gillam 2016) | Phase 3 RCT | 417 | Liposomal irinotecan + 5-FU/LV after gemcitabine | Median OS 6.1 vs 4.2 mo (post-progression) |
| Isaji 2018 — IAP Borderline Consensus | Consensus / SR | — | Definition of borderline resectable PDAC | Anatomic and biological criteria framework |
| Springfeld 2023 (Nat Rev Clin Oncol) | Narrative review of RCTs | — | Neoadjuvant therapy state of the art | Synthesis across resectability categories |
Key Findings on Pancreatic Cancer Treatment Synthesised by Theme
Five themes emerge from the synthesis of randomised trials, consensus statements, and pivotal cohort studies on pancreatic cancer treatment. They span resectability classification, neoadjuvant strategy in borderline resectable disease, adjuvant regimens, first-line metastatic care, and the evolving role of multidisciplinary tumor board review.
Theme 1 — Resectability Classification Drives Pathway Selection
The 2018 International Association of Pancreatology consensus, paralleled by NCCN definitions, stratifies patients into resectable, borderline resectable, locally advanced, and metastatic categories. Stratification is anatomic (vascular involvement of SMA, celiac, hepatic artery, SMV/PV) and biological (CA 19-9 elevation, performance status, suspected occult metastasis).
Borderline resectable disease is defined by tumor abutment of major arteries up to 180° or venous involvement amenable to reconstruction. Pancreatic cancer treatment pathways diverge sharply at this point: clearly resectable disease may proceed to upfront surgery or neoadjuvant therapy, while borderline disease has shifted decisively toward a neoadjuvant-first approach in modern practice.
Theme 2 — Neoadjuvant Therapy in Resectable and Borderline Resectable Disease
PREOPANC randomised 246 patients with resectable or borderline resectable disease to neoadjuvant gemcitabine-based chemoradiation followed by surgery and adjuvant gemcitabine, versus immediate surgery and adjuvant gemcitabine. Long-term follow-up demonstrated 5-year overall survival of 20.5% versus 6.5% (HR 0.73; 95% CI 0.56–0.96; p=0.025).
ESPAC-5F, although limited by small sample size, showed a consistent direction of effect for neoadjuvant chemotherapy over immediate surgery in borderline resectable disease. The A021501 phase 2 trial established that mFOLFIRINOX without radiotherapy meets prespecified efficacy thresholds in borderline resectable cases. Together these trials anchor a neoadjuvant-first approach for borderline disease in modern pancreatic cancer treatment.
Theme 3 — Adjuvant Therapy After Resection
PRODIGE 24 / CCTG PA.6 randomised 493 patients with resected pancreatic ductal adenocarcinoma to adjuvant modified FOLFIRINOX or gemcitabine. Median overall survival was 54.4 versus 35.0 months (HR 0.64; 95% CI 0.48–0.86; p=0.003), and disease-free survival was 21.6 versus 12.8 months. Modified FOLFIRINOX is now the preferred adjuvant regimen for fit patients.
For patients unable to tolerate FOLFIRINOX, ESPAC-4 supports adjuvant gemcitabine plus capecitabine over gemcitabine alone (median OS 28.0 vs 25.5 months; HR 0.82). Capacity to receive optimal adjuvant therapy is a key argument for the neoadjuvant approach: more patients receive intended systemic therapy when it is delivered before, rather than after, a major pancreatic resection.
Theme 4 — First-Line Metastatic Disease and NAPOLI 3
FOLFIRINOX (PRODIGE 4 / ACCORD 11) and gemcitabine plus nab-paclitaxel (MPACT) have been the dominant first-line options for over a decade. NAPOLI 3 randomised 770 treatment-naive metastatic patients to NALIRIFOX (liposomal irinotecan, oxaliplatin, 5-FU, leucovorin) versus gemcitabine plus nab-paclitaxel. Median overall survival was 11.1 versus 9.2 months (HR 0.84; 95% CI 0.71–0.99).
Choice between NALIRIFOX, FOLFIRINOX, and gemcitabine plus nab-paclitaxel hinges on performance status, prior exposure, neuropathy, and biliary anatomy. Both triplet regimens (NALIRIFOX, FOLFIRINOX) require adequate performance status and biliary drainage; gemcitabine plus nab-paclitaxel remains the preferred option for less fit patients.
Theme 5 — Multidisciplinary Care and Biomarker-Guided Selection
Multidisciplinary tumor board review at diagnosis is now standard of care across NCCN, ESMO, and national guidelines. Concordance between board recommendations and delivered pancreatic cancer treatment is consistently associated with better outcomes in registry analyses.
Germline and somatic testing now influences a meaningful minority of patients: BRCA1/2 mutations support consideration of platinum-based regimens and PARP inhibitor maintenance, while KRAS G12C and microsatellite instability identify a small but actionable subset for targeted or immunotherapy approaches. Biomarker testing has become a routine component of modern pancreatic cancer treatment for advanced disease.
Synthesis pearl: Modern pancreatic cancer treatment decisions answer four sequential questions: (1) what is the resectability category? (2) is the patient fit for triplet chemotherapy? (3) does biomarker testing alter the regimen? (4) is the chosen pathway endorsed by the multidisciplinary tumor board with capacity for timely escalation?
Quality & Consistency of Evidence
The evidence base supporting modern pancreatic cancer treatment is robust for systemic therapy regimens but more uneven for surgical timing in clearly resectable disease. The colored ratings below reflect study design strength, replication, and consistency of effect across populations and pancreatic cancer treatment settings.
What the Evidence Does Not Show
Despite mature evidence in adjuvant therapy and metastatic regimens, several clinically important questions about pancreatic cancer treatment remain unsettled. Acknowledging these gaps protects against overconfident extrapolation and frames where active research is most needed.
The open questions cluster around the role of radiotherapy in neoadjuvant pathways, the optimal sequencing of triplet chemotherapy in advanced disease, and how to apply biomarker-guided therapy in a tumor type where actionable mutations remain a minority.
Specific Knowledge Gaps
- Neoadjuvant therapy in clearly resectable disease. PREOPANC-2, NEOPAC, and NORPACT have not consistently shown a survival advantage over upfront surgery plus adjuvant therapy in clearly resectable patients. The optimal pathway remains contested.
- Role of radiotherapy in neoadjuvant settings. A021501 suggests SBRT may not add benefit to mFOLFIRINOX. The relative contribution of chemoradiation versus chemotherapy alone in borderline resectable disease is still being defined.
- Head-to-head triplet comparison. NAPOLI 3 compared NALIRIFOX with gemcitabine plus nab-paclitaxel rather than with FOLFIRINOX. Direct NALIRIFOX vs FOLFIRINOX trials are pending.
- Optimal sequencing across treatment lines. Whether NALIRIFOX in first line and gemcitabine plus nab-paclitaxel in second line outperforms the reverse sequence lacks head-to-head data.
- Biomarker-guided therapy beyond BRCA. KRAS G12C and G12D inhibitors, claudin 18.2 antibodies, and immunotherapy in microsatellite stable disease show preliminary signals; phase 3 confirmation is awaited.
- Older and frail populations. Most trials enrolled patients with ECOG 0–1; the optimal regimen and dose for ECOG 2 and elderly patients lacks robust trial data.
Practical Implications for Pancreatic Cancer Treatment
Based on the current evidence, contemporary pancreatic cancer treatment decisions can be framed as evidence-supported considerations rather than rigid algorithms. Patient-level factors — performance status, comorbidity, biliary anatomy, biomarker profile, and patient preference — always modify the synthesised positions below.
The four cards summarise the highest-confidence applications. The accordions that follow address adjacent operational issues — surgical centre volume, biliary drainage, and post-operative surveillance — that recur in routine pancreatic cancer treatment practice.
Pancreatoduodenectomy outcomes are highly volume-sensitive. National registry analyses consistently demonstrate lower 90-day mortality, lower failure-to-rescue, and higher rates of textbook recovery at high-volume centres. Multidisciplinary infrastructure — interventional radiology, hepatobiliary surgery, dedicated pancreatic pathology — co-varies with volume and may underlie part of the observed advantage.
Where geography or insurance limits referral, partnership models (regional tumor board review, surgical mentorship, second-opinion pathways) can narrow the volume-outcome gap. Routine reporting of textbook outcome rather than mortality alone provides a more complete picture of centre performance for pancreatic cancer treatment.
Many patients with head-of-pancreas tumors present with obstructive jaundice. Biliary drainage with self-expanding metal stents is the preferred approach in most modern pathways, with plastic stents reserved for short-duration drainage. Triplet chemotherapy regimens generally require bilirubin to be controlled before initiation.
Cholangitis after stenting is a significant cause of treatment delay. Antibiotic prophylaxis at the time of ERCP, and close surveillance for stent occlusion, are practical levers to keep patients on schedule for systemic therapy. Delays of more than 2–3 weeks in starting neoadjuvant or first-line therapy correlate with worse outcomes in registry data.
Recurrence after curative-intent pancreatic resection is common and most often occurs within the first 2 years. NCCN and ESMO endorse surveillance with cross-sectional imaging and CA 19-9 every 3–6 months for at least 2 years post-resection, then less frequently thereafter.
Patterns of recurrence — local, peritoneal, hepatic, pulmonary — influence the choice of subsequent therapy. Oligometastatic recurrence in carefully selected patients may be amenable to local therapy, although the evidence base for metastasis-directed therapy in pancreatic cancer remains less mature than in colorectal disease.
Evidence Grade & Bottom Line
Evidence Grade — Strong (adjuvant mFOLFIRINOX after resection; first-line metastatic intensive regimens; PREOPANC long-term neoadjuvant data in borderline resectable); Moderate (resectability classification; neoadjuvant chemotherapy in borderline resectable per ESPAC-5F and A021501); Limited (routine neoadjuvant therapy in clearly resectable disease; biomarker-guided therapy beyond BRCA; optimal triplet sequencing).
Bottom Line
- Pancreatic cancer treatment is fundamentally stratified by resectability category, with each setting mapping to a distinct evidence-based pathway.
- For borderline resectable disease, PREOPANC long-term and supporting trials support a neoadjuvant-first approach with chemotherapy ± radiation tailored to fitness and centre experience.
- After R0/R1 resection in fit patients, adjuvant modified FOLFIRINOX is the standard regimen, with gemcitabine plus capecitabine a validated alternative for those unable to tolerate triplet therapy.
- For metastatic pancreatic cancer treatment, NALIRIFOX joins FOLFIRINOX and gemcitabine plus nab-paclitaxel as a first-line option, with regimen selection guided by performance status, biomarker profile, and prior exposure.
- Persistent gaps include the role of neoadjuvant therapy in clearly resectable disease, optimal triplet sequencing, and how best to integrate emerging biomarker-targeted therapies — areas where individualised judgement supplements published evidence.
Article Information & References
Disclaimer
For Educational Purposes Only. This is an original evidence synthesis informed by the studies listed below. It does not replace clinical judgement. Drug dosages should be verified against current prescribing information.
References
- Versteijne E, van Dam JL, Suker M, et al. Neoadjuvant Chemoradiotherapy Versus Upfront Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Long-Term Results of the Dutch Randomized PREOPANC Trial. J Clin Oncol. 2022;40(11):1220-1230. DOI: 10.1200/JCO.21.02233
- Versteijne E, Suker M, Groothuis K, et al. Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial. J Clin Oncol. 2020;38(16):1763-1773. DOI: 10.1200/JCO.19.02274
- Ghaneh P, Palmer D, Cicconi S, et al. Immediate Surgery Compared With Short-Course Neoadjuvant Gemcitabine Plus Capecitabine, FOLFIRINOX, or Chemoradiotherapy in Patients With Borderline Resectable Pancreatic Cancer (ESPAC5). Lancet Gastroenterol Hepatol. 2023;8(2):157-168. DOI: 10.1016/S2468-1253(22)00348-X
- Katz MHG, Shi Q, Meyers J, et al. Efficacy of Preoperative mFOLFIRINOX vs mFOLFIRINOX Plus Hypofractionated Radiotherapy for Borderline Resectable Adenocarcinoma of the Pancreas: The A021501 Phase 2 Randomized Clinical Trial. JAMA Oncol. 2022;8(9):1263-1270. DOI: 10.1001/jamaoncol.2022.2319
- Conroy T, Hammel P, Hebbar M, et al. FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer. N Engl J Med. 2018;379(25):2395-2406. DOI: 10.1056/NEJMoa1809775
- Neoptolemos JP, Palmer DH, Ghaneh P, et al. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet. 2017;389(10073):1011-1024. DOI: 10.1016/S0140-6736(16)32409-6
- Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer. N Engl J Med. 2011;364(19):1817-1825. DOI: 10.1056/NEJMoa1011923
- Von Hoff DD, Ervin T, Arena FP, et al. Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine. N Engl J Med. 2013;369(18):1691-1703. DOI: 10.1056/NEJMoa1304369
- Wainberg ZA, Melisi D, Macarulla T, et al. NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial. Lancet. 2023;402(10409):1272-1281. DOI: 10.1016/S0140-6736(23)01366-1
- Wang-Gillam A, Li CP, Bodoky G, et al. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. Lancet. 2016;387(10018):545-557. DOI: 10.1016/S0140-6736(15)00986-1
- Isaji S, Mizuno S, Windsor JA, et al. International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017. Pancreatology. 2018;18(1):2-11. DOI: 10.1016/j.pan.2017.11.011
- Springfeld C, Ferrone CR, Katz MHG, et al. Neoadjuvant therapy for pancreatic cancer. Nat Rev Clin Oncol. 2023;20(5):318-337. DOI: 10.1038/s41571-023-00746-1